The Adiponectin Testing Market is estimated to be valued at USD 56.7 billion in 2025 and is projected to reach USD 121.2 billion by 2035, registering a compound annual growth rate (CAGR) of 7.9% over the forecast period.
The adiponectin testing market is witnessing steady growth due to increasing research focus on metabolic disorders and their biomarkers. Adiponectin is recognized for its role in insulin sensitivity and cardiovascular health, driving demand for precise testing in clinical and research settings. Advances in assay technologies have enabled more accurate and sensitive detection, supporting both diagnostic and therapeutic research.
Research and academic institutes have expanded their capabilities to explore adiponectin’s role across various diseases, which has further boosted testing demand. Increasing investments in metabolic syndrome and diabetes research globally have also contributed to market growth.
The expansion of healthcare infrastructure in emerging regions and growing awareness about obesity-related health risks are additional factors supporting the market. Segment growth is expected to be led by assay kits, human species testing, and research and academic institutes as the primary end users.
The market is segmented by Product Type, Species Type, and End User and region. By Product Type, the market is divided into Assay Kits and Reagents & Consumables. In terms of Species Type, the market is classified into Human, Mouse, Rat, and Others.
Based on End User, the market is segmented into Research & Academic Institutes, Hospitals, and Diagnostic Labs. Regionally, the market is classified into North America, Latin America, Western Europe, Eastern Europe, Balkan & Baltic Countries, Russia & Belarus, Central Asia, East Asia, South Asia & Pacific, and the Middle East & Africa.
The assay kits segment is projected to hold 46.3% of the adiponectin testing market revenue in 2025, retaining its leading position. The growth of this segment has been driven by the convenience and reliability of assay kits that allow rapid and accurate quantification of adiponectin levels in biological samples. Their ease of use and standardized protocols have made them the preferred choice for laboratories and research centers.
Technological improvements have enhanced sensitivity and specificity, enabling better disease correlation studies. The availability of ready-to-use kits has reduced assay time and variability, increasing throughput in research applications.
With the rising prevalence of metabolic diseases, the demand for assay kits is expected to continue its upward trajectory.
The human species testing segment is anticipated to account for 51.7% of the market revenue in 2025, leading the species type category. This is due to the extensive research and clinical interest in human adiponectin as a biomarker for conditions such as diabetes, obesity, and cardiovascular diseases. Clinical studies and trials often require human-specific testing to understand disease mechanisms and treatment responses.
The segment benefits from improved assay designs tailored to human samples, which provide higher accuracy and reproducibility. Increasing focus on personalized medicine and biomarker-driven diagnostics further supports growth in this segment.
The demand for human adiponectin testing is expected to remain strong as metabolic disorder research advances.
The research and academic institutes segment is projected to contribute 39.6% of the adiponectin testing market revenue in 2025, securing its place as the leading end user. Growth in this segment has been fueled by the increasing number of studies focusing on adiponectin’s role in metabolic regulation and disease pathogenesis. Academic institutions have expanded their testing capabilities to support translational research and biomarker discovery.
The availability of grant funding and government support for metabolic and cardiovascular research has further encouraged assay adoption in these institutes. Collaboration between academic centers and clinical research organizations has facilitated extensive use of adiponectin testing in experimental and clinical studies.
As research on obesity-related conditions and metabolic syndromes intensifies, the demand from research and academic users is expected to maintain a robust growth rate.
The increasing research and development activities are the main factor that is responsible for increasing the demand for adiponectin testing kits.
An increasing number of research laboratories and diagnostic laboratories is expected to augment the sales of adiponectin testing kits.
Sales of adiponectin testing kits are growing owing to other factors, such as the increasing number of hospitals and increasing healthcare expenditure.
Increasing disposable income in various countries is also considered a major fuller in demand for adiponectin testing kits.
There are a few factors that can hinder the overall demand for adiponectin testing kits. One of them is the high cost of adiponectin tests, and the same is expected to impede the sales of adiponectin testing kits. Lack of awareness in some of the developing regions and poor availability of medical facilities in a few developing economies are also limiting the demand for adiponectin testing kits.
Sales of adiponectin testing kits are on the surge as these are simple and easy to perform and are majorly used for research purposes. The adiponectin kits are very convenient to use and hence, can increase the demand for adiponectin testing kits.
On the basis of geography, the global adiponectin testing market has been segmented into several key regions, i.e., North America, Latin America, Europe, East Asia, South Asia, Oceania, and MEA.
North America is expected to hold a large adiponectin testing market share due to the presence of a large number of hospitals and advanced healthcare infrastructure.
Europe is also expected to hold a large adiponectin testing market share, and the same can be attributed to the increasing population.
The Asia Pacific is also expected to show significant growth in the sales of adiponectin testing kits due to the increasing research and developmental activities.
The manufacturing companies use different strategies, like new product launches and acquisitions, which are expected to augment the adiponectin testing market share. The report consists of key players contributing to the adiponectin testing market share. It also consists of organic and inorganic growth strategies adopted by market players to improve their market positions.
Some of the key players present in the global adiponectin testing market are Eagle Biosciences, Boster Biological Technology, Merck KGaA, Thermo Fisher Scientific Inc., Biorad laboratories, Stratech, etc.
| Report Attribute | Details |
|---|---|
| Base year for estimation | 2024 |
| Historical data | 2020 to 2024 |
| Forecast period | 2025 to 2035 |
| Quantitative units | Revenue in million and CAGR from 2025 to 2035 |
| Report coverage | Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis, |
| Segments covered | Type, End Use and Region |
| Regional scope | North America; Western Europe; Eastern Europe; Middle East; Africa; ASEAN; South Asia; Rest of Asia; Australia and New Zealand |
| Country scope | USA, Canada, Mexico, Germany, UK, France, Italy, Spain, Russia, Belgium, Poland, Czech Republic, China, India, Japan, Australia, Brazil, Argentina, Colombia, Saudi Arabia, UAE, Iran, South Africa |
| Key companies profiled | Eagle Biosciences; Boster Biological Technology; Merck KGaA; Thermo fisher Scientific Inc.; Biorad laboratories etc.; Stratech etc. |
| Customization scope | Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. |
The global adiponectin testing market is estimated to be valued at USD 56.7 billion in 2025.
It is projected to reach USD 121.2 billion by 2035.
The market is expected to grow at a 7.9% CAGR between 2025 and 2035.
The key product types are assay kits and reagents & consumables.
human segment is expected to dominate with a 51.7% industry share in 2025.
Explore Similar Insights
Adiponectin Testing Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
Chat With
MaRIA
